<DOC>
	<DOCNO>NCT02604485</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical pharmacology single dose pharmacokinetics pharmacodynamics XOMA 358 subject hypoglycemia associate congenital hyperinsulinism .</brief_summary>
	<brief_title>A Single-Dose Open-Label Study XOMA 358 Subjects With Congenital Hyperinsulinism</brief_title>
	<detailed_description />
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<criteria>Clinical diagnosis congenital hyperinsulinism Duration glucose level less 70mg/dL , CGM , average least 120 minute day across baseline Days 3 , 2 , 1 single duration less 60 minute baseline Days 3 , 2 , 1 , unless subject receive rescue treatment . Can safely washout background medication use treat hyperinsulinism . Use agent , diazoxide , octreotide , chronic systemic glucocorticoid , β agonist may affect glucose metabolism Body Mass Index ≥ 35 kg/m2 Pregnant female , female plan become pregnant course study , female deliver 3 month screen , breastfeed Male subject plan pregnancy female partner course study within 4 month administration study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypoglycemia</keyword>
	<keyword>Congenital Hyperinsulinism</keyword>
</DOC>